Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), ...

Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia ® (denosumab), to treat a variety of ...

BioVersys strengthens its Ansamycin Chemistry platform and research on tackling difficult-to-treat non-tuberculous mycobacteria (NTM) diseases. BioVersys joins forces with Hackensack Meridian Health ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult‑to‑treat bacterial ...

Hangzhou Tigermed Consulting Co., Ltd. ('Tigermed' or the 'company') (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical ...

Closed upsized initial public offering in February 2026, raising $381 million in gross proceedsCompleted enrollment of the TeLuRide-005 Phase 2 trial of EIK1001 in first-line treatment of stage 4 ...

From an enslaved Bostonian who helped save smallpox victims to scientists behind the COVID-19 vaccine, National Doctors' Day honors American healers.

Over one billion people worldwide are over 60, and the population is projected to more than double by 2050. But as more ...

Here are a few lessons learned from growing into today’s biopharma landscape and how leaders can apply them in their own organizations.

It involves substances “not for human use.” ...

Paradigm Biopharma (ASX:PAR) has officially passed a milestone that gives investors in the company a ‘fast-track’ path to ...